Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 12, 2008, Pages 3495-3499

  Xu, Guozhang ^a   Searle, Lily Lee ^a   Hughes, Terry V ^a   Beck, Amanda K ^a   Connolly, Peter J ^a   Abad, Marta C ^a   Neeper, Michael P ^a   Struble, Geoffrey T ^a   Springer, Barry A ^a   Emanuel, Stuart L ^a   Gruninger, Robert H ^a   Pandey, Niranjan ^a   Adams, Mary ^a   Moreno Mazza, Sandra ^a   Fuentes Pesquera, Angel R ^a   Middleton, Steven A ^a   Greenberger, Lee M ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Bioisostere; EGFR; ErbB 2; Oxime; Quinazoline; Receptor tyrosine kinase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; OXIME DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDROGEN BONDING; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OXIMES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44849136560     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.05.024     Document Type: Article

References (31)

1. Olayioye M.A., Neve R.M., Lane H.A., and Hynes N.E. EMBO J. 19 (2000) 3159
2. Salomon D.S., Bradt R., Ciardiello F., and Normanno N. Crit. Rev. Oncol. Hematol. 19 (1995) 183
3. Black J.D., Brattain M.G., Krishnamurthi S.A., Dawson D.M., and Willson J.K. Curr. Opin. Invest. Drugs 4 (2003) 1451
4. Gullick W.J. Br. Med. Bull. 47 (1991) 87
5. Woodburn J.R. Pharmacol. Ther. 82 (1999) 241
6. Seymour L. Curr. Opin. Invest. Drugs 4 (2003) 658
7. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson I.C., and Norton L. J. Clin. Oncol. 14 (1996) 737
8. Waksal H.W. Cancer Metastasis Rev. 18 (2000) 427
9. Gschwind A., Fisher O.M., and Ullrich A. Nature (2004) 361
10. Rusnak D.W., Lackey K., Affleck K., Wood E.R., Alligood K.J., Rhodes N., Keith B.R., Murray D.M., Knight W.B., Mullin R.J., and Gilmer T.M. Mol. Cancer Ther. 1 (2001) 85
11. Stamo J., Sliwkowski M.X., and Eigenbrot C.J. J. Biol. Chem. 48 (2002) 46265
12. Liao J.J. J. Med. Chem. 50 (2007) 409
13. Huang S., Li R., Connolly P.J., Xu G., Gaul M.D., Emanuel S.L., LaMontagne K.R., and Greenberger L.M. Bioorg. Med. Chem. Lett. 16 (2006) 6063
14. Gaul M.D., Xu G., Kirkpatrick J., Ott H., and Baumann C.A. Bioorg. Med. Chem. Lett. 17 (2007) 4861
15. Gomtsyan A., Didomenico S., Lee C., Matulenko M.A., Kim K., Kowaluk E.A., Wismer C.T., Mikusa J., Yu H., Kohlhaas K., Jarvis M.F., and Bhagwat S.S. J. Med. Chem. 45 (2002) 3639
16. Tsou H., Overbeek-Klumpers E., Hallett W., Reich M., Floyd M.B., Johnson B.D., Michalak R.S., Nilakantan R., Discafani C., Golas J., Rabindran S.K., Shen R., Shi X., Wang Y., Upeslacis J., and Wissner A. J. Med. Chem. 48 (2005) 1107
17. Ram S., Wise D.S., and Townsend L.B. J. Heterocyclic Chem. 23 (1986) 1109
18. Pal M., Subramanian CV., and Yeleswarapu K.R. Tetrahedron Lett. 44 (2003) 8221
19. Mastalerz H., Chang M., Chen P., Dextraze P., Fink B., Gavai A., Goyal B., Han W., Johnson W., Langley D., Lee F.Y., Marathe P., Mathur A., Oppenheimer S., Ruediger E., Tarrant J., Tokarski J.S., Vite G.D., Vyas D.M., Wong H., Wong T.W., Zhang H., and Zhang G. Bioorg. Med. Chem. Lett. 17 (2007) 2036
20. Cockerill S., Stubberfield C., Stables J., Carter M., Guntrip S., Smith K., MaKeown S., Shaw R., Topley P., Thomsen L., Affeck K., Jowett A., Hayes D., Willson M., Woollard P., and Spalding D. Bioorg. Med. Chem. Lett. 11 (2001) 1401
21. 50 values were calculated with standard deviation from 2 to 8 separate experiments.
22. Bhattacharya S.K., Cox E.D., Kath J.C., Mathiowetz A.M., Morris J., Moyer J.D., Pustilnik L.R., Rafidi K., Richter D.T., Su C., and Wessel M.D. Biochem. Biophys. Res. Commun 307 (2003) 267
23. Brignola P.S., Lackey K., Kadwell S.H., Hoffman C., Horne E., Carter H.L., Stuart J.D., Blackburn K., Moyer M.B., Alligood K.J., Knight W.B., and Wood E.R. J. Bio. Chem. 277 (2002) 1576
24. 14C-thymidine incorporation into cellular DNA as described. Emanuel S., et al. Mol. Pharm. 66 (2004) 635 except that total time in which cells were exposed to drug was 96 h
25. Upstate Cell Signaling Solutions, Charlottesville, VA.
26. PDB code is 3BEL.
27. S671-G998) which was confirmed by DNA sequencing. This expression construct was then integrated into bacmid DNA and a recombinant isolate used to tansfect SF9 insect cells as recommended by the vendor. The resulting baculovirus was then used to infect additional Sf9 cells to increase viral titer and volume.
28. EGFR purification. All purification processes were carried out on an ÄKTA FPLC system (GE Healthcare) at 4 °C. The purification protocol was performed as described previously [J. Biol. Chem. (2002), 277, p. 46265-46272,]. Briefly, frozen cells were thawed and resuspended in 50 mM Tris pH 7.5, 200 mM NaCl, 1% glycerol, 5 mM BME, 1 X complete EDTA-free protease inhibitor cocktail (Roche). Resuspended cells were dounce homogenized and mechanically lysed with an Emulsiflex-C5 (Avestin) at 10,000-15,000 psi. The lysate was clarified by centrifugation at 40,000g for 1 h. The supernatant was filtered through a 0.8 μm vacuum filter and mixed to a TALON metal affinity resin (BD Biosciences) overnight at 4 °C. The lysate-TALON mixture was loaded into a column and washed with 10 column volumes of Buffer A (50 mM Tris pH 8.0, 500 mM NaCl, 5 mM imidazole.) EGFR was eluted using a 10 column volume linear gradient going from Buffer A to Buffer B (50 mM Tris pH 8.0, 300 mM NaCl, 250 mM Imidazole.) Fractions containing EGFR, as assayed by SDS-PAGE, were pooled. Thrombin was added to the pooled protein to remove the histidine tag (0.005 U of thrombin/μg EGFR). The reaction was dialyzed overnight against 50 mM Tris buffer pH 8.0, 250 mM NaCl, 1 mM DTT. Cleaved EGFR was filtered through a 0.2 μm SFCA cartridge filter, concentrated, and loaded onto a Superdex 200 HR 10/30 column (GE Healthcare,) preequilibrated with 50 mM Tris pH 8.0, 500 mM NaCl, 1 mM DTT. Fractions containing EGFR, as assayed by SDS-PAGE, were pooled and dialyzed against 10 mM Tris pH 8.0, 1 mM DTT, 1 mM sodium azide, 0.1 mM benzamidine.
29. 16 All model building was done using O [Jones, T. A., Zou, J. Y., Cowan, S. W., Kjeldgaard, M. (1991) Acta Crystallogr A47, 110-119] and refinement and map calculations were carried out using CNX [Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., Warren, G. L. (1998) Acta Crystallogr D 54, 905-921]. The final structure was refined to an Rfactor of 22.7 and Rfree of 26.7.
30. Rusnak D.W., Affleck K., Cockerill S.G., Stubberfield C., Harris R., Page M., Smith K.J., Guntrip S.B., Carter M.C., Shaw R.J., Jowett A., Stables J., Topley P., Wood E.R., Brignola P.S., Kadwell S.H., Reep B.R., Mullin R.J., Alligood K.J., Keith B.R., Crosby R.M., Murray D.M., Knight W.B., Gilmer T.M., and Lackey K. Cancer Res. 61 (2001) 7196
31. Gaul M.D., Guo Y., Affleck K., Cockerill G.S., Gilmer T.M., Griffin R.J., Guntrip S., Keith B.R., Knight W.B., Mullin R.J., Murray D.M., Rusnak D.W., Smith K., Tadepalli S., Wood E.R., and Lackey K. Bioorg. Med. Chem. Lett. 13 (2003) 637